Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Immutep Limited (NASDAQ:IMMP) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, the company shared that ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...